Value-based pricing: UK drug industry shifts influence away from HTA body
This article was originally published in SRA
The UK pharma industry association, the ABPI, has won a victory over NICE, the health technology appraisal institute for England and Wales, in the ongoing negotiations over value-based pricing. Currently, NICE sets the cost-effectiveness thresholds that influence UK drug pricing and the role of NICE itself was outside the ABPI’s sphere of influence. However, the ABPI's chief executive Stephen Whitehead told Scrip Regulatory Affairs sister publication Scrip Intelligence, that those thresholds are now part of the negotiations rather than being outside them.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.